Systemic treatment of locally advanced or metastatic penile cancer

被引：0

作者：

Gassian, Noemie ^{[1
]}

Frontczak, Alexandre ^{[2
]}

El Kaddissi, Antoine ^{[1
]}

Calcagno, Fabien ^{[1
]}

Almotlak, Hamadi ^{[1
]}

Barkatz, Johann ^{[2
]}

Mouillet, Guillaume ^{[1
]}

Maurina, Tristan ^{[1
]}

Stein, Ulrich ^{[1
]}

Thierry Nguyen Tan Hon ^{[1
]}

Murez, Thibaut ^{[3
]}

Thiery-Vuillemin, Antoine ^{[1
,4
]}

机构：

[1] CHU Besancon, Oncol, F-25030 Besancon, France

[2] CHU Besancon, Urol, F-25030 Besancon, France

[3] CHU Montpellier, Urol, F-34295 Montpellier, France

[4] INSERM, UMR1098, F-25020 Besancon, France

来源：

BULLETIN DU CANCER | 2020年 / 107卷 / 05期

关键词：

Penile cancer; Chemotherapy; Immunotherapy; Targeted therapy; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; HUMAN-PAPILLOMAVIRUS; CISPLATIN; CHEMOTHERAPY; METHOTREXATE; COMBINATION; PACLITAXEL; BLEOMYCIN; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.

引用

页码：S17 / S23

页数：7

共 50 条

[1] Current status of systemic treatment in locally advanced and metastatic bladder cancer
De Mulder, PHM
[J]. RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 281 - 290
[2] Systemic chemotherapy in locally advanced and/or metastatic bladder cancer
Pectasides, D.
Pectasides, M.
Economopoulos, Th.
[J]. CANCER TREATMENT REVIEWS, 2006, 32 (06) : 456 - 470
[3] Treatment of Locally Advanced/Metastatic Colorectal Cancer
Venook, Alan P.
Willett, Christopher G.
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 617 - 621
[4] Treatment of locally advanced and metastatic bladder cancer
Khochikar, Makarand V.
[J]. INDIAN JOURNAL OF UROLOGY, 2008, 24 (01) : 84 - 94
[5] Treatment of locally advanced and metastatic gastric cancer
Klein, HO
[J]. MEDIZINISCHE WELT, 1997, 48 (09): : 401 - 404
[6] Review of systemic therapies for locally advanced and metastatic rectal cancer
Yaffee, Patrick
Osipov, Arsen
Tan, Carlyn
Tuli, Richard
Hendifar, Andrew
[J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (02) : 185 - 200
[7] New systemic therapies for locally advanced and metastatic thyroid cancer
Herrick, Cynthia J.
Moley, Jeffrey F.
[J]. INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2016, 3 (02) : 143 - 159
[8] Approach to Treatment and its Outcome in Locally Advanced Penile Cancer
Thomson, D.
Elliott, T.
[J]. CLINICAL ONCOLOGY, 2011, 23 (03) : S56 - S56
[9] The systemic treatment of advanced and metastatic bladder cancer
Hussain, SA
James, ND
[J]. LANCET ONCOLOGY, 2003, 4 (08): : 489 - 497
[10] Current treatment of locally advanced and metastatic prostate cancer
Ponholzer A.
Steinbacher F.
Madersbacher S.
Schramek P.
[J]. Wiener Medizinische Wochenschrift, 2011, 161 (15-16) : 377 - 381

← 1 2 3 4 5 →